WallStreetZenWallStreetZen

NASDAQ: ITCI
Intra Cellular Therapies Inc Earnings & Revenue

ITCI past revenue growth

How has ITCI's revenue growth performed historically?
Company
65.45%
Industry
9.98%
Market
15.15%
ITCI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ITCI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ITCI's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ITCI earnings and revenue history

Current Revenue
$513.9M
Current Earnings
-$110.9M
Current Profit Margin
-21.6%

ITCI Return on Equity

Current Company
-18.5%
Current Industry
13.8%
Current Market
28.2%
ITCI's Return on Equity (-18.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ITCI announces earnings.

ITCI Return on Assets

Current Company
-15.3%
Current Industry
3.8%
ITCI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ITCI Return on Capital Employed

Current Company
-17.95%
Current Industry
5.7%
ITCI has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ITCI vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ITCI$513.93M-$109.36M-$110.87M+360.37%N/A
LNTH$1.37B$674.08M$460.53M+31.50%+43.70%
ELAN$4.37B-$325.00M-$1.30B+7.35%N/A
ALKS$1.73B$438.76M$434.43M+9.59%N/A
PRGO$4.56B$405.80M-$7.70M-0.58%N/A

ITCI earnings dates

Next earnings date
Jun 14, 2024

Intra Cellular Therapies Earnings & Revenue FAQ

What were ITCI's earnings last quarter?

On Invalid Date, Intra Cellular Therapies (NASDAQ: ITCI) reported Q1 2024 earnings per share (EPS) of -$0.16, up 65.22% year over year. Total Intra Cellular Therapies earnings for the quarter were -$15.25 million. In the same quarter last year, Intra Cellular Therapies's earnings per share (EPS) was -$0.46.

If you're new to stock investing, here's how to buy Intra Cellular Therapies stock.

What was ITCI's earnings growth in the past year?

As of Q2 2024, Intra Cellular Therapies's earnings has grown year over year. Intra Cellular Therapies's earnings in the past year totalled -$110.87 million.

What is ITCI's earnings date?

Intra Cellular Therapies's earnings date is Invalid Date. Add ITCI to your watchlist to be reminded of ITCI's next earnings announcement.

What was ITCI's revenue last quarter?

On Invalid Date, Intra Cellular Therapies (NASDAQ: ITCI) reported Q1 2024 revenue of $144.87 million up 52% year over year. In the same quarter last year, Intra Cellular Therapies's revenue was $95.31 million.

What was ITCI's revenue growth in the past year?

As of Q2 2024, Intra Cellular Therapies's revenue has grown 65.45% year over year. This is 55.47 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.98%. Intra Cellular Therapies's revenue in the past year totalled $513.93 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.